Treatment of Interstitial Lung Disease Associated Cough CHEST Guideline and Expert Panel Report
Surinder S Birring, Joanne E Kavanagh, Richard S Irwin, Karina A Keogh, Kaiser G Lim, Jay H Ryu
CHEST | ELSEVIER SCIENCE BV | Published : 2018
BACKGROUND: Chronic cough in interstitial lung disease (ILD) causes significant impairment in quality of life. Effective treatment approaches are needed for cough associated with ILD. METHODS: This systematic review asked: Is there evidence of clinically relevant treatment effects for therapies for cough in ILD? Studies of adults aged > 18 years with a chronic cough ≥ 8 weeks' duration were included and assessed for relevance and quality. Based on the systematic review, guideline suggestions were developed and voted on by using CHEST guideline methodology. RESULTS: Eight randomized controlled trials and two case series (≥ 10 patients) were included that reported data on patients with idiopat..View full abstract
The authors have reported to CHEST the following: S. S. B. has received scientific advisory board/consultancy fees from Merck, Bayer, Patara, and Menlo; speaker fees from Roche; and conference travel from Boehringer Ingelheim. None declared (J. E. K., R. S. I., K. A. K., K. G. L., J. H. R.).